Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
RESPONSE BIOMEDICAL CORP (RBM) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/02/2016 8-K Quarterly results
11/15/2016 8-K Form 8-K - Current report
08/16/2016 8-K Quarterly results
Docs: "Response Biomedical Corp. Announces Second Quarter 2016 Financial Results and Filing of Definitive Proxy Statement for Special Meeting of Shareholders VANCOUVER, British Columbia – August 12, 2016 - Response Biomedical Corp. a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its second quarter and six months ended June 30, 2016. Total revenue for the second quarter of 2016 was $1.3M and totaled $3.5M for the first half of 2016, a reduction of 69% and 55% respectively relative to the the comparable periods of 2015. While our sales to our China distributors have suffered during the transition to our new distribution network, our sales in the rest of the world continue to see year over year growt..."
06/20/2016 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Arrangement Agreement, between the Company and 1077801 B.C. Ltd., a company owned by OrbiMed Asia Partners, LP, OrbiMed Private Investments III, LP and OrbiMed Associates III, LP and Shanghai Runda Medical Technology Co., Ltd",
"Form of Subscription Agreement",
"Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement"
06/15/2016 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Docs: "Response Biomedical Corp. Announces Voting Results VANCOUVER, B.C., June 13, 2016 - Response Biomedical Corp. , in accordance with the requirements of the Toronto Stock Exchange, is pleased to announce the results of voting at its 2016 Annual General and Special Meeting of Shareholders held earlier today. A total of 6,110,535 common shares were represented at the meeting, representing approximately 62% of the issued and outstanding common shares of the Company. Shareholders voted as follows: 1. Election of Directors By resolution passed by show of hands, the number of Directors of the Company was set at seven. By resolution passed by ballot vote, the following seven nominees proposed by Management were elected as Directors of the Company to hold office until the next Annual Meeting of Shar..."
05/19/2016 8-K Quarterly results
Docs: "Response Biomedical Corp. Announces First Quarter 2016 Financial Results VANCOUVER, British Columbia – May 16, 2016 - Response Biomedical Corp. a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its first quarter ended March 31, 2016, including a 2016 GAAP net loss of $, or $ per share, compared with a GAAP net loss of $, or $ per share in 2015, and 2016 negative Adjusted EBITDA of $, compared with a negative Adjusted EBITDA of $ in 2015. “Sales in China in the first quarter of 2016 continued to be a challenge for us. We were successful in increasing non-China sales by 16%, improving gross margin by 10 percentage points and reducing operating costs by 15% thereby reducing our Adjusted EBITDA l..."
03/23/2016 8-K Quarterly results
Docs: "Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2015 Financial Results VANCOUVER, British Columbia – March 21, 2016 - Response Biomedical Corp. a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its fourth quarter and year ended December 31, 2015, including a 2015 GAAP net loss of $, or $ per share, compared with a GAAP net loss of $, or $ per share in 2014, and 2015 Adjusted EBITDA of $822,000, compared with a negative Adjusted EBITDA of $ in 2014. “We are pleased to report our first full year of Adjusted EBITDA profitable growth with a 40% increase to $15.4 million in total revenue in 2015 - $3.4 million in Joinstar collaboration revenue and $12.0 million in product sales. This..."
11/08/2013 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Response Biomedical Corp. Announces Conversion of Subscription Receipts VANCOUVER, British Columbia – November 7, 2013 - Response Biomedical Corp. is pleased to announce that shareholders of Response have approved the conversion of 1,273,117 subscription receipts for gross proceeds of approximately $3.1 million. The Subscription Receipts were issued in connection with the Company’s previously announced brokered and non-brokered private placements . At the special meeting of shareholders held on November 7, 2013 , disinterested shareholders of Response approved the issuance of the Subscription Receipts on the terms described more fully in the Company’s October 17, 2013 information circular. The Company has provided notice to the subscription receipt agent that the escrow release conditions..."
08/13/2013 8-K Quarterly results
Docs: "Response Biomedical Corp. Announces 2013 Second Quarter Financial Results VANCOUVER, British Columbia – August 13, 2013 - Response Biomedical Corp. today reported financial results for the quarter and six months ended June 30, 2013. The Company reported sales of $2.7 million in the second quarter of 2013, a 10% decline from second quarter, 2012. The Company’s gross margin increased 3.7 percentage points versus Q2, 2012, growing from 37.9% to 41.6%. Operating expenses declined 19% to $2.1M this quarter versus last year. GAAP net income of 2013 was $3.3 million, up 40% versus the same period last year. Adjusted Net Loss, which excludes the non-cash impact of the warrant liability, decreased to $1.1 million compared to $1.6 million in the comparative quarter last year. The Company’s adjusted..."
07/30/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement and Mutual Release, by and between Response Biomedical Corp. and Patricia Massitti"
03/01/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Response Biomedical Corp. announces the hire of Mr. Darby L. Darilek as Director of U.S. Sales to expand its presence and commitment to the U.S. market Vancouver, British Columbia, February 26, 2013 - Response Biomedical Corp. is pleased to announce that Mr. Darby L. Darilek joined the Company on February 25, 2013 as its Director of U.S. Sales. “This is an important hire for Response as we continue to solidify our plans to gain U.S. market share for our well-received product portfolio. This strategic hire comes on the heels of a successful U.S. FDA audit, the launch of the RAMP 200 in the U.S. for use in laboratory settings and the recent signing of two significant U.S. based distribution agreements. We are pleased that Mr. Darilek has chosen to join Response at this critical juncture and..."
01/25/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Response Biomedical Corp. announces execution of new distribution agreement with Fisher HealthCare for U.S. Distribution of its Response Infectious Disease Products Vancouver, British Columbia, January 24, 2013 - Response Biomedical Corp. announced today that it has entered into a new nonexclusive distribution agreement with Fisher HealthCare, part of Thermo Fisher Scientific to distribute its Infectious Disease portfolio of RAMP products in the U.S. Fisher HealthCare is a global distributor of innovative diagnostic technologies and laboratory products to hospitals, physician office laboratories and alternate healthcare settings. This is the second agreement entered into between Response's newly formed, wholly owned U.S. subsidiary, Response Point of Care Inc., and a U.S. distributor in J..."
01/04/2013 8-K Other Events, Financial Statements and Exhibits
11/15/2012 8-K Quarterly results
Docs: "Response Biomedical Corp. Announces Third Quarter 2012 Financial Results VANCOUVER, British Columbia – November 14, 2012 - Response Biomedical Corp. today reported financial results for the three and nine months ended September 30, 2012. “We are encouraged by our financial results for the quarter, which show continued revenue growth and strengthening of our gross margin over the comparative period last year” said Jeff Purvin, Chief Executive Officer. “We now have a new management team in place and we look forward to expanding the global reach of our sales while continuing to support the markets that have brought us this far.” Financial results for the three months ended September 30, 2012"
11/09/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Response Biomedical Corp.: Patricia Massitti, 604-456-6010 VP, Administration & Corporate Communications [email protected]"
09/25/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Response Biomedical Corp. Announces Share Consolidation Vancouver, British Columbia – September 24, 2012 - Response Biomedical Corp. , announced today the completion of the consolidation of issued and outstanding common shares of the Company on the basis of every twenty Common Shares being consolidated into one Common Share . The Company expects the post-Consolidation Common Shares to begin trading on the Toronto Stock Exchange and the OTC Bulletin Board in the United States on or about September 26, 2012. No fractional Common Shares will be issued pursuant to the Consolidation and shareholders will not receive cash in lieu of fractional Common Shares resulting from the Consolidation. The post-Consolidation Common Shares will be represented by a new CUSIP, but there will be no changes in t..."
08/20/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Response Biomedical Corporation Announces Share Consolidation VANCOUVER, British Columbia - August 16, 2012 - Response Biomedical Corp. , announced today that, in accordance with the authority granted by shareholders at the Company’s special and annual general meeting held on June 19, 2012 to implement a consolidation of the issued and outstanding common shares of the Company on the basis of every twenty Common Shares being consolidated into one Common Share , the board of directors has decided to proceed with the Consolidation. The Company has received conditional approval from the Toronto Stock Exchange to effect the Consolidation. Subject to the Company receiving final approval from the TSX, the effective date of the Consolidation is expected to be on or about September 24, 2012. It is ..."
08/10/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between Response Biomedical Corp. and W.J. Bill Adams",
"Response Biomedical Corporation Announces Appointment of W.J. Adams as CFO & Corporate Secretary and Resignation of Richard A. Canote as CFO VANCOUVER, British Columbia – August 9, 2012 – Response Biomedical Corporation today reported that the Board of Directors of the Company has appointed Mr. Bill Adams as Chief Financial Officer and Corporate Secretary effective August 13, 2012. Mr. Adams has assumed the role of CFO replacing Richard Canote who has resigned as CFO but will continue with the Company for a period in a consulting capacity. Mr. Adams is a Chartered Accountant with over 20 years of strategic financial management experience in both public and private companies. He was Chief Financial Officer of CellFor Inc., a B.C.-based company that manufactures tree seedlings for forest la..."
07/30/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Response Biomedical Corporation Announces Appointment of Dr. Jonathan Wang as Director DRAFT VANCOUVER, British Columbia – July 30, 2012 - Response Biomedical Corporation today reported that effective July 25, 2012, the Board of Directors of the Company have appointed Jonathan Wang, Ph.D. as a Director. Dr. Wang was a previous Director of the Company from July 27, 2010 to October 20, 2011. Mr. Jeffrey Purvin stated “We are very pleased to have Dr. Jonathan Wang return to the Board of Directors. During his previous term on the board, as well as in the interim period, Jonathan provided important insights into the China market for Response’s point of care products. His long experience in China will be enormously valuable in expanding our presence there”. Dr. Wang is a Senior Managing Directo..."
07/27/2012 8-K Form 8-K - Current report
06/29/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Consulting Agreement, by and between Response Biomedical Corp. and Jeffrey L. Purvin"
06/25/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2008 Stock Option Plan"
05/08/2012 8-K Quarterly results
Docs: "Response Biomedical Corporation Announces First Quarter 2012 Financial Results VANCOUVER, British Columbia – May 7, 2012 - Response Biomedical Corporation today reported financial results for the three months ended March 31, 2012. Financial results for the period ended March 31, 2012 · Product sales of $2.98 million for the three months ended March 31, 2012, compared to $2.02 million for the three months ended March 31, 2011. o Cardiovascular sales have increased to $2.68 million during the three months ended March 31, 2012, compared to $1.53 million in the comparative period in 2011. An increase in sales to China was the primary driver of this growth. o Infectious disease, Bio-defense, and Vector Infectious Disease sales decreased to $0.30 million during the three months ended March 31, 2..."
05/03/2012 8-K Changes in Registrant's Certifying Accountant, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Letter from Ernst & Young LLP"
04/13/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between Response Biomedical Corporation and Jeffrey L. Purvin",
"Response Biomedical Corporation Announces Agreement with Jeffrey L. Purvin to become Chief Executive Officer VANCOUVER, British Columbia – April 13, 2012 - Response Biomedical Corporation today reported that the Company has reached an agreement with Mr. Jeffrey L. Purvin to become its new Chief Executive Officer, effective May 1, 2012. “We are delighted that Jeff has agreed to become our next CEO”, said Dr. Peter A. Thompson, Executive Chairman and Interim CEO. “Jeff’s background and experience is perfectly suited to help drive Response during this very exciting time for the Company.” Mr. Purvin has over 30 years of experience marketing both consumer and medical products. From November 2006 to December 2011, he was the Chairman and CEO of Calibra Medical, Inc., where he and his team develo..."
03/29/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting Agreement, by and between Response Biomedical Corporation and Richard Canote"
03/28/2012 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
03/28/2012 8-K Quarterly results
Docs: "Response Biomedical Corporation Announces 2011 Financial Results VANCOUVER, British Columbia – March 28, 2012 - Response Biomedical Corporation today reported financial results for the year ending December 31, 2011. Financial results for the year ended 2011"
01/06/2012 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy